Social Media Vaping Cessation Pilot With Peer Mentors

February 25, 2026 updated by: University of California, San Francisco

Single-Arm Social Media Vaping Cessation Trial With Peer Mentors

The purpose of this study is to understand the feasibility and acceptability of integrating peer mentoring into a social media-based intervention to help adolescents and young adults quit e-cigarette use.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a one-arm pilot trial with adolescent and young adult e-cigarette users. This study tested a peer-mentored program to help teens and young adults quit vaping using social media. Participants joined one of two inter groups and received messages from a trained counselor over 5 weeks. Each group also included two peer mentors who had successfully quit vaping and offered support. Participants completed surveys before and after the program.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
27

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • University of California, San Francisco

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria for intervention participants:

  1. English literacy;
  2. aged 13 to 21;
  3. use social media at least four days per week;
  4. vape at least once per week in the past 30 days;
  5. are considering or interested in quitting within the next six months or 30 days; and
  6. resided in California.

Inclusion criteria for peer mentors:

  1. English literacy;
  2. aged 18-29;
  3. have quit e-cigarettes for more than 3 months;
  4. are willing to participate in an approximately 2-hour online training and pass the test after training; and
  5. will commit to provide support to help peers quit vaping in Instagram groups for 5 weeks (approximately 20 mins/day).

Exclusion criteria for intervention participants:

Individuals who do not meet the inclusion criteria.

Exclusion criteria for peer mentors:

Those who report using other tobacco products or substances and those with active mental health conditions will be excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Peer-Mentored Vaping Cessation Intervention
Adolescents and young adults received the Quit the Hit (QTH) vaping cessation program delivered via Instagram over 5 weeks. A trained counselor posted 1-3 evidence-based vaping cessation messages per weekday. Each group included two peer mentors, aged similarly to participants, who had successfully quit vaping and provided social support and guidance. Participants completed baseline and follow-up surveys.
Behavioral: Quit the Hit (QTH) Program with Peer Mentoring
The QTH program delivered 1-3 evidence-based vaping cessation messages per weekday via Instagram over 5 weeks. Peer mentors, aged similarly to participants and who had successfully quit vaping, provided social support, encouragement, and one-on-one direct messaging.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Feasibility: Engagement and retention
Time Frame: 5 Weeks
Engagement measured by number of posts and likes in the Instagram group. Retention defined as proportion completing the 5-week follow-up survey.
5 Weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Perceived Usefulness of Peer Mentoring
Time Frame: 5 Weeks
Perceived usefulness was assessed in the follow-up survey with 9 statements, measuring agreement using a 5-point Likert scale (1 disagree a lot to 5 agree a lot). Example items included "the peer mentors helped me quit vaping," "the peer mentors shared useful information on quitting," and "the peer mentors increased my confidence that I can quit."
5 Weeks
Satisfaction with Peer Mentoring
Time Frame: 5 Weeks
Satisfaction with peer mentoring was assessed with six statements on the follow-up survey, measuring agreement using a 5-point Likert scale (1 = disagree a lot to 5 = agree a lot). Items included "I liked the peer mentoring in the program," "I felt comfortable with the messages I got from peer mentors," "the peer mentors sent messages at convenient times of day," etc. Additionally, participants rated their satisfaction with the quantity of peer mentor posts on a 5-point scale by responding to the item
5 Weeks
Evaluation of the program
Time Frame: 5 Weeks
The overall evaluation of the peer mentored vaping cessation program was measured using four statements, measuring agreement on a 5-point Likert scale (1 = disagree a lot to 5 = agree a lot). The four items were "I would recommend this program to others", "The program gave me something new to think about", "I thought about what I read in the program", and "The program was easy to understand."
5 Weeks
Self-Reported 7-Day Point Prevalent Abstinence (PPA) from vaping
Time Frame: 5 Weeks
7-day point prevalence abstinence (PPA) will be assessed via the question about the number of days they used e-cigarettes in the past 7 days at the end of the intervention. Participants reporting no vaping in the past 7 days will be coded as abstinent.
5 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of California, San Francisco

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Cancer Institute (NCI)
Tobacco Related Disease Research Program

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Pamela M Ling, MD, University of California, San Francisco
  • Principal Investigator: Chen Joanne Lyu, PhD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 19, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 30, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 3, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 20, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • F32CA265059 (U.S. NIH Grant/Contract)
  • T31IR1910 (Other Grant/Funding Number: Tobacco Related Diseases Research Program)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Support

Clinical Trials on Quit the Hit (QTH) Program with Peer Mentoring

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings